Traws Pharma, Inc. (TRAW) — Financial statements
Income statement, balance sheet, and cash flow for Traws Pharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3↑1134.5% | 0.23↑0.0% | 0.23↑0.0% | 0.23↑0.0% | 0.23 | |
| Cost of Revenue | 0.00↓100.0% | 0.01 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 3↑1203.7% | 0.21↓5.3% | 0.23↑0.0% | 0.23↑0.0% | 0.23 | |
| Operating Expenses | ||||||
| R&D Expenses | 12↓90.7% | 130↑1040.1% | 11↑0.2% | 11↑56.3% | 7 | |
| General & Administrative Expenses | 9↓30.7% | 12↑35.1% | 9↑7.7% | 8↓10.4% | 9 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↓30.7% | 12↑35.1% | 9↑7.7% | 8↓10.4% | 9 | |
| Other Expenses | 0.00↑100.0% | -93 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 21↓58.3% | 50↑141.5% | 21↑3.4% | 20↑18.7% | 17 | |
| Total Costs & Expenses | 21↓58.3% | 50↑141.5% | 21↑3.4% | 20↑18.7% | 17 | |
| Operating Results | ||||||
| Operating Income | -18↑63.8% | -49↓143.1% | -20↓3.4% | -20↓19.0% | -16 | |
| Depreciation & Amortization | 0.06↑408.3% | 0.01↓25.0% | 0.02↑14.3% | 0.01↑0.0% | 0.01 | |
| EBITDA | -18↑89.3% | -167↓721.0% | -20↓3.4% | -20↓19.0% | -16 | |
| EBIT | -18↑89.3% | -167↓720.4% | -20↓3.4% | -20↓19.0% | -16 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↓100.0% | 117 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 27↑123.1% | -117↓8779.6% | 1↑103.6% | 0.66↑99.1% | 0.33 | |
| Income Before Tax | 9↑105.5% | -167↓778.8% | -19↑0.1% | -19↓17.3% | -16 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 9↑105.5% | -167↓778.8% | -19↑0.1% | -19↓17.3% | -16 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 9↑116.8% | -55↓188.5% | -19↑0.1% | -19↓17.3% | -16 | |
| Bottom-Line Net Income | 7↑112.6% | -55↓188.5% | -19↑0.1% | -19↓17.3% | -16 | |
| EPS (Basic) | 0.83↑102.4% | -35.21↓56.0% | -22.57↑0.5% | -22.68↑5.5% | -24.01 | |
| EPS (Diluted) | 0.82↑102.3% | -35.21↓56.0% | -22.57↑0.5% | -22.68↑5.5% | -24.01 | |
| Weighted Average Shares | 8↑429.9% | 2↑84.9% | 0.84↑0.4% | 0.84↑24.2% | 0.67 | |
| Weighted Average Diluted Shares | 8↑439.5% | 2↑84.9% | 0.84↑0.4% | 0.84↑24.2% | 0.67 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.